| Species |
Cynomolgus |
| Protein Construction |
PCSK9 (Glu151-Gln811)
Accession # A0A2K5TZC4 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized PCSK9, His, Cynomolgus at 5μg/ml (100μl/Well) on the plate. Dose response curve AntiPCSK9 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
the pro-form (59 kDa) and mature form (14 kDa) |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 65-70 kDa (pro-form) and 15-20 kDa (mature form) based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated. |
| Synonyms |
PCSK9 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
